# EDGAR Filing Document

**Accession Number:** 0001287865
**File Stem:** 0001193125-25-170123
**Filing Date:** 2025-7
**Character Count:** 79996
**Document Hash:** dc10f8b4947ce2e8798bc405bc87f829
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-170123.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001193125-25-170123

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20250731

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MEDICAL PROPERTIES TRUST INC
- **CENTRAL INDEX KEY:** 0001287865
- **STANDARD INDUSTRIAL CLASSIFICATION:** REAL ESTATE INVESTMENT TRUSTS [6798]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32559
- **FILM NUMBER:** 251169581

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 URBAN CENTER DRIVE
- **STREET 2:** SUITE 501
- **CITY:** BIRMINGHAM
- **STATE:** AL
- **ZIP:** 35242
- **BUSINESS PHONE:** 205-969-3755

**MAIL ADDRESS:**
- **STREET 1:** 1000 URBAN CENTER DRIVE
- **STREET 2:** SUITE 501
- **CITY:** BIRMINGHAM
- **STATE:** AL
- **ZIP:** 35242

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### Date of report (Date of earliest event reported): July 31, 2025

## MEDICAL PROPERTIES TRUST, INC.

#### (Exact Name of Registrant as Specified in Charter)

#### Commission File Number 001-32559

---

| | |
|:---|:---|
| **Maryland** | **20-0191742** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **1000 Urban Center Drive, Suite 501**<br> **Birmingham, AL** | **35242** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code
(205) 969-3755

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc. | MPW | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.**  |

---

On July 31, 2025, Medical Properties Trust, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference in any filing of Medical Properties Trust, Inc. with the Securities and Exchange Commission, except as expressly set forth by specific reference in any such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) *Exhibits*.

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | [Press release dated July 31, 2025 reporting financial results for the three and six months ended June 30, 2025](d67253dex991.htm) |
| 99.2 | [Medical Properties Trust, Inc. 2<sup>nd</sup> Quarter 2025 Supplemental Information](d67253dex992.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.

---

| | |
|:---|:---|
| **MEDICAL PROPERTIES TRUST, INC.** | **MEDICAL PROPERTIES TRUST, INC.** |
| By: | /s/ R. Steven Hamner |
| Name: | R. Steven Hamner |
| Title: | Executive Vice President and Chief Financial Officer |

---

Date: July 31, 2025

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g67253g0731081748374.jpg)

Contact: Drew Babin, CFA, CMA Head of Financial Strategy and Investor Relations Medical Properties Trust, Inc. (646) 884-9809 <u>dbabin@medicalpropertiestrust.com</u>

**MEDICAL PROPERTIES TRUST, INC. REPORTS SECOND QUARTER RESULTS AND UPDATE** 

***Rapid Growth in Cash Rents from New Operators***

***Recent Transactions Continue to Validate Asset Values and Provide Balance Sheet Flexibility***

**Birmingham, AL – July 31, 2025 –** Medical Properties Trust, Inc. (the "Company" or "MPT") (NYSE: MPW) today announced financial and operating results for the second quarter ended June 30, 2025, as well as certain events occurring subsequent to quarter end.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of ($0.16) and Normalized Funds from Operations ("NFFO") of $0.14 for the 2025 second quarter
on a per share basis. Second quarter net loss includes approximately $111 million ($0.18 per share) in impairment and fair market value adjustments primarily related to the completed sale of PHP Holdings and certain Prospect Medical Group
("Prospect") bankruptcy transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash rental income from new tenants increased to $11.0 million from the first quarter's
$3.4 million, representing 96% of scheduled collections; scheduled cash collections for the third quarter approximate $17 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Increased equity investment in Infracore joint venture by approximately CHF 50 million, inclusive of a CHF
25 million short-term loan, in April to facilitate the acquisition of a Swiss general acute facility and repayment of debt;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• During the second quarter, sold a post-acute facility with most recent annualized cash rents of approximately
$4 million for aggregate proceeds of approximately $28 million and an approximate $5 million real estate gain;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As the result of a competitive process indicative of robust demand for hospital real estate, the Company's
50% owned joint venture completed a €702.5 million non-recourse, 10-year non-amortizing loan at a 5.1% fixed rate
secured by a portfolio of German rehabilitation hospitals; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Paid a regular quarterly dividend of $0.08 per share in July.

Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer, said, "During the quarter, our portfolio of new operators continued to successfully ramp operations around the country. As expected, rental income from these operators increased significantly quarter-over-quarter and, in turn, we remain confident in our visibility to annualized pro rata cash rent of more than $1 billion by the fourth quarter of 2026."

------

Aldag continued, "We have executed multiple highly successful debt offerings in 2025, including our German joint-venture's recent €702.5 million refinancing transaction at a 5.1% fixed rate. These transactions continue to serve as important validation of investor appetite for hospital real estate assets, the long-term strength of MPT's global portfolio, and the growth opportunities embedded in our platform."

Included in the financial tables accompanying this press release is information about the Company's assets and liabilities, operating results, and reconciliations of net loss to NFFO, including per share amounts, all on a basis comparable to 2024 results.

**PORTFOLIO UPDATE** 

Medical Properties Trust has total assets of approximately $15.2 billion, including $9.1 billion of general acute facilities, $2.5 billion of behavioral health facilities and $1.7 billion of post-acute facilities. As of June 30, 2025, MPT's portfolio included 392 properties and approximately 39,000 licensed beds leased to or mortgaged by 53 hospital operating companies across the United States as well as in the United Kingdom, Switzerland, Germany, Spain, Finland, Colombia, Italy and Portugal.

Across regions and asset types, operators are reporting increased admissions and surgical volumes, resulting in increasing TTM EBITDARM coverage for the total portfolio and for each individual asset class on both a year-over-year and sequential basis.

In Europe, hospitals continue to benefit from strong reimbursement and patient acuity trends, and three operators in MPT's U.K. portfolio were nominated for HealthInvestors' Private Hospital Group of the Year – Circle Health, Priory, and Ramsay.

Performance in the United States continues to be driven by increased admissions, volumes and particularly strong performance in inpatient rehabilitation facilities. In early July, U.S. Congress passed the One Big Beautiful Bill Act ("OBBBA"), introducing Medicaid funding changes over the next decade that are expected to allow ample time for hospital operators to adapt their businesses as necessary while increasing demand for flexible capital solutions over the near- and long-term.

The new tenants to which MPT has transferred the operations of properties in Florida, Texas, Arizona, Louisiana and Pennsylvania continue to report improving performance trends as they ramp operations. Through the second quarter, and with the exception of approximately $500,000 in rent related to two facilities, MPT has collected all cash rent owed by these tenants. Presently, three tenants are paying fully ramped cash rent, and both HonorHealth and College Health are underway with self-funded capital spending initiatives.

Prospect's in-court restructuring process which commenced in January 2025 remains underway. In March, the Bankruptcy Court approved a settlement agreement between MPT, Prospect and certain other parties that will enable Prospect to sell its hospital operations and the related real estate with MPT's cooperation. During and subsequent to the second quarter, the Company funded approximately $25 million of junior debtor-in-possession financing according to the settlement agreement.

**OPERATING RESULTS** 

Net loss for the second quarter ended June 30, 2025 was ($98 million) (($0.16) per share), compared to a net loss of ($321 million) (($0.54) per share) in the year earlier period.

------

NFFO for the second quarter ended June 30, 2025 was $81 million ($0.14 per share), compared to $139 million ($0.23 per share) in the year-earlier period. Compared to 2025's first quarter results, NFFO for 2025's second quarter included an overall increase in rent billed of approximately $13 million ($0.02 per share) and an offsetting increase in interest expense of approximately $14 million ($0.02 per share) related to the $2.5 billion secured notes financing completed in the first quarter.

**CONFERENCE CALL AND WEBCAST** 

The Company has scheduled a conference call and webcast for July 31, 2025 at 11:00 a.m. Eastern Time to present the Company's financial and operating results for the quarter ended June 30, 2025. The dial-in numbers for the conference call are 800-715-9871 (North America) and 646-307-1963 (International) along with passcode 5278552. The conference call will also be available via webcast in the Investor Relations section of the Company's website, <u>www.medicalpropertiestrust.com</u>.

A telephone and webcast replay of the call will be available beginning shortly after the call's completion. The telephone replay will be available through August 7, 2025, using dial-in numbers 800-770-2030 (North America) and 609-800-9909 (International) along with passcode 5278552. The webcast replay will be available for one year following the call's completion on the Investor Relations section of the Company's website.

The Company's supplemental information package for the current period will also be available on the Company's website in the Investor Relations section.

*The Company uses, and intends to continue to use, the Investor Relations page of its website, which can be found at* <u>www.medicalpropertiestrust.com</u>, *as a means of disclosing material nonpublic information and of complying with its disclosure obligations under Regulation FD, including, without limitation, through the posting of investor presentations that may include material nonpublic information. Accordingly, investors should monitor the Investor Relations page, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.*

**About Medical Properties Trust, Inc.** 

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world's largest owners of hospital real estate with 392 facilities and approximately 39,000 licensed beds in nine countries and across three continents as of June 30, 2025. MPT's financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. For more information, please visit the Company's website at <u>www.medicalpropertiestrust.com</u>.

**Forward-Looking Statements** 

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "would", "could", "expect", "intend", "plan", "estimate", "target", "anticipate", "believe", "objectives", "outlook", "guidance" or other similar words, and include statements regarding our strategies, objectives, asset sales and other liquidity transactions (including the use of proceeds thereof), expected re-tenanting of facilities and any related regulatory approvals, and expected outcomes from Prospect's Chapter 11 restructuring process. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual

------

results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) the risk that the timing, outcome and terms of the bankruptcy restructuring of Prospect will not be consistent with those anticipated by the Company; (ii) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate acquisitions and investments; (iii) the risk that previously announced or contemplated property sales, loan repayments, and other capital recycling transactions do not occur as anticipated or at all; (iv) the risk that MPT is not able to attain its leverage, liquidity and cost of capital objectives within a reasonable time period or at all; (v) MPT's ability to obtain or modify the terms of debt financing on attractive terms or at all, as a result of changes in interest rates and other factors, which may adversely impact our ability to pay down, refinance, restructure or extend our indebtedness as it becomes due, or pursue acquisition and development opportunities; (vi) the ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us; (vii) the ability of our tenants and operators to operate profitably and generate positive cash flow, remain solvent, comply with applicable laws, rules and regulations in the operation of our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract patients; (viii) the risk that we are unable to monetize our investments in certain tenants at full value within a reasonable time period or at all; (ix) the risk that the operations of our tenants will be negatively impacted by changes to Medicaid funding introduced by the OBBBA; and (x) the risks and uncertainties of litigation or other regulatory proceedings.

The risks described above are not exhaustive and additional factors could adversely affect our business and financial performance, including the risk factors discussed under the section captioned "Risk Factors" in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q, and as may be updated in our other filings with the SEC. Forward-looking statements are inherently uncertain and actual performance or outcomes may vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned to not place undue reliance on forward-looking statements as predictions of future events. We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made.

*# # #* 

------

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES** 

Consolidated Balance Sheets

---

| | | |
|:---|:---|:---|
| ***(Amounts in thousands, except for per share data)*** | June 30, 2025 | December 31, 2024 |
|  | **(Unaudited)** | **(A)** |
|  **Assets** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Land, buildings and improvements, intangible lease assets, and other | $11892237 | $11259842 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investment in financing leases | 1023415 | 1057770 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate held for sale |  | 34019 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mortgage loans | 123887 | 119912 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gross investment in real estate assets | 13039539 | 12471543 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accumulated depreciation and amortization | (1599587) | (1422948) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net investment in real estate assets | 11439952 | 11048595 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | 509828 | 332335 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest and rent receivables | 28644 | 36327 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Straight-line rent receivables | 825845 | 700783 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investments in unconsolidated real estate joint ventures | 1360151 | 1156397 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investments in unconsolidated operating entities | 323383 | 439578 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other loans | 149018 | 109175 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other assets | 513607 | 471404 |
|  **Total Assets** | $**15150428** | $**14294594** |
|  **Liabilities and Equity** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debt, net | $9649035 | $8848112 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable and accrued expenses | 494783 | 454209 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue | 23513 | 29445 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Obligations to tenants and other lease liabilities | 149287 | 129045 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Liabilities | 10316618 | 9460811 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred stock, $0.001 par value. Authorized 10,000 shares; no shares outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common stock, $0.001 par value. Authorized 750,000 shares; issued and outstanding - 600,814 shares at June 30, 2025 and 600,403 shares at December 31, 2024 | 601 | 600 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additional paid-in capital | 8598211 | 8584917 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retained deficit | (3971824) | (3658516) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accumulated other comprehensive income (loss) | 205768 | (94272) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Medical Properties Trust, Inc. stockholders' equity | 4832756 | 4832729 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-controlling interests | 1054 | 1054 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Equity | 4833810 | 4833783 |
|  **Total Liabilities and Equity** | $**15150428** | $**14294594** |

---

**(A)** Financials have been derived from the prior year audited financial statements.

------

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES** 

Consolidated Statements of Income

(Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(Amounts in thousands, except for per share data)*** | For the Three Months Ended | For the Three Months Ended | For the Six Months Ended | For the Six Months Ended |
|  | June 30, 2025 | June 30, 2024 | June 30, 2025 | June 30, 2024 |
|  **Revenues** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rent billed | $177860 | $183764 | $343050 | $383063 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Straight-line rent | 39665 | 38381 | 79792 | 83117 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income from financing leases | 9923 | 27641 | 19828 | 44034 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest and other income | 12911 | 16774 | 21488 | 27662 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total revenues | 240359 | 266560 | 464158 | 537876 |
|  **Expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest | 129709 | 101430 | 245510 | 210115 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate depreciation and amortization | 66717 | 102240 | 131289 | 177826 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Property-related (A) | 10863 | 7663 | 17898 | 12481 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General and administrative | 26197 | 35327 | 68108 | 68675 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total expenses | 233486 | 246660 | 462805 | 469097 |
|  **Other (expense) income** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gain on sale of real estate | 5212 | 384824 | 13271 | 383401 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate and other impairment charges, net | (1421) | (137419) | (77523) | (830507) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Earnings (loss) from equity interests | 25324 | (401757) | 39310 | (391208) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debt refinancing and unutilized financing benefit (costs) | 181 | (2964) | (3615) | (2964) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other (including fair value adjustments on securities) | (124434) | (167686) | (169640) | (397031) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total other expense | (95138) | (325002) | (198197) | (1238309) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss before income tax | (88265) | (305102) | (196844) | (1169530) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income tax expense | (9803) | (14557) | (19240) | (25506) |
|  **Net loss** | **(98068)** | **(319659)** | **(216084)** | **(1195036)** |
|  Net income attributable to non-controlling interests | (289) | (976) | (548) | (1224) |
|  **Net loss attributable to MPT common stockholders** | $**(98357)** | $**(320635)** | $**(216632)** | $**(1196260)** |
|  **Earnings per common share - basic and diluted:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net loss attributable to MPT common stockholders** | $**(0.16)** | $**(0.54)** | $**(0.36)** | $**(1.99)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Weighted average shares outstanding - basic** | **600814** | **600057** | **600733** | **600181** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Weighted average shares outstanding - diluted** | **600814** | **600057** | **600733** | **600181** |
|  **Dividends declared per common share** | $**0.08** | $**0.30** | $**0.16** | $**0.30** |

---

(A) Includes $5.1 million and $4.9 million of ground lease and other expenses (such as property taxes and
insurance) paid directly by us and reimbursed by our tenants for the three months ended June 30, 2025 and 2024, respectively, and $7.1 and $7.2 million for the six months ended June 30, 2025 and 2024, respectively.

------

**MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES** 

Reconciliation of Net Loss to Funds From Operations

(Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***(Amounts in thousands, except for per share data)*** | For the Three Months Ended | For the Three Months Ended | For the Six Months Ended | For the Six Months Ended |
|  | June 30, 2025 | June 30, 2024 | June 30, 2025 | June 30, 2024 |
|  **FFO information:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net loss attributable to MPT common stockholders** | $**(98357)** | $**(320635)** | $**(216632)** | $**(1196260)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Participating securities' share in earnings | (224) | (654) | (341) | (654) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net loss, less participating securities' share in earnings | $(98581) | $(321289) | $(216973) | $(1196914) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization | 81332 | 117239 | 158223 | 211482 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gain on sale of real estate | (5212) | (384824) | (13271) | (383401) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate impairment (recoveries) charges | (17715) | 499324 | 47968 | 499324 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Funds from operations** | $**(40176)** | $**(89550)** | $**(24053)** | $**(869509)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other impairment charges, net | 19613 | 50073 | 33511 | 744978 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Litigation, bankruptcy and other costs | 2156 | 11738 | 12203 | 17608 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Share-based compensation (fair value adjustments) (A) | (9540) |  | (13) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash fair value adjustments | 108827 | 159247 | 135436 | 380523 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tax rate changes and other | 19 | 4895 | 1121 | 4588 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debt refinancing and unutilized financing costs | 463 | 2964 | 4259 | 2964 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Normalized funds from operations** | $**81362** | $**139367** | $**162464** | $**281152** |
|  **Certain non-cash and related recovery information:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Share-based compensation (A) | $10397 | $8521 | $18535 | $16154 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debt costs amortization | $6984 | $4936 | $12990 | $9775 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash rent and interest revenue (B) | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash recoveries of non-cash rent and interest revenue (C) | $538 | $540 | $1064 | $6288 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Straight-line rent revenue from operating and finance leases | $(42638) | $(40786) | $(85257) | $(88032) |
|  **Per diluted share data:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net loss, less participating securities' share in earnings** | $**(0.16)** | $**(0.54)** | $**(0.36)** | $**(1.99)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization | 0.13 | 0.20 | 0.26 | 0.35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gain on sale of real estate | (0.01) | (0.64) | (0.02) | (0.64) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real estate impairment (recoveries) charges | (0.03) | 0.83 | 0.08 | 0.83 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Funds from operations** | $**(0.07)** | $**(0.15)** | $**(0.04)** | $**(1.45)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other impairment charges, net | 0.04 | 0.08 | 0.05 | 1.25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Litigation, bankruptcy and other costs |  | 0.02 | 0.02 | 0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Share-based compensation (fair value adjustments) (A) | (0.02) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash fair value adjustments | 0.19 | 0.27 | 0.23 | 0.63 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tax rate changes and other |  | 0.01 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debt refinancing and unutilized financing costs |  |  | 0.01 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Normalized funds from operations** | $**0.14** | $**0.23** | $**0.27** | $**0.47** |
|  **Certain non-cash and related recovery information:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Share-based compensation (A) | $0.02 | $0.01 | $0.03 | $0.03 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debt costs amortization | $0.01 | $0.01 | $0.02 | $0.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash rent and interest revenue (B) | $— | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash recoveries of non-cash rent and interest revenue (C) | $— | $— | $— | $0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Straight-line rent revenue from operating and finance leases | $(0.07) | $(0.07) | $(0.14) | $(0.15) |

---

Notes:

Investors and analysts following the real estate industry utilize funds from operations ("FFO") as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate Investment Trusts, or Nareit, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization, including amortization related to in-place lease intangibles, and after adjustments for unconsolidated partnerships and joint ventures.

In addition to presenting FFO in accordance with the Nareit definition, we disclose normalized FFO, which adjusts FFO for items that relate to unanticipated or non-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts. We believe that the use of FFO, combined with the required GAAP presentations, improves the understanding of our operating results among investors and the use of normalized FFO makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs (if any not paid by our tenants) to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our results of operations or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity.

Certain line items above (such as depreciation and amortization) include our share of such income/expense from unconsolidated joint ventures. These amounts are included with all activity of our equity interests in the "Earnings (loss) from equity interests" line on the consolidated statements of income.

(A) Total share-based compensation expense is $0.9 million and $18.5 million for the three and six months
ended June 30, 2025, respectively, (including certain awards that are to be settled in cash). Cash-settled awards are typically recorded in accordance with GAAP at fair value and measured at each balance sheet date until settlement. The
resulting fluctuations, which are primarily driven by changes in our stock price rather than operational performance, can introduce significant volatility in our earnings. To enhance comparability and provide a more stable view of performance over
time, NFFO reflects a $(9.5) million and less than $(0.1) million adjustment in the three and six months ended June 30, 2025, respectively, to arrive at total share-based compensation expense using grant date fair value for all awards
(including cash-settled awards) of $10.4 million and $18.5 million for the three and six months ended June 30, 2025.

(B) Includes revenue accrued during the period but not received in cash, such as deferred rent, payment-in-kind ("PIK") interest or other accruals.

(C) Includes cash received to satisfy previously accrued non-cash revenue,
such as the cash receipt of previously deferred rent or PIK interest.

## Exhibit 99.2

QUARTERLY SUPPLEMENTAL 2Q 2025 AT T H E V E R Y H E A R T O F H E A LT H C A R E .®

**Exhibit 99.2**![LOGO](g67253g11a01.jpg)

------

COMPANY OVERVIEW FORWARD-LOOKING STATEMENTS 3 This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section Company Information 3 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "would", "could", "expect", "intend", "plan", FINANCIAL INFORMATION "estimate", "target", "anticipate", "believe", "objectives", "outlook", "guidance" or other similar words, and include statements regarding our strategies, objectives, asset sales and other liquidity transactions Reconciliation of Funds from Operations 6 (including the use of proceeds thereof), expected re-tenanting of facilities and any related regulatory approvals, and expected outcomes from 6 Debt Summary 7 Prospect's Chapter 11 restructuring process. Forward-looking statements involve known and unknown risks and uncertainties that may cause our Debt Maturities and Debt Metrics 8 actual results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) the risk that the timing, outcome and terms of the bankruptcy restructuring of Prospect will not be consistent with those anticipated by PORTFOLIO INFORMATION the Company; (ii) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate Lease and Loan Maturity Schedule 9 acquisitions and investments; (iii) the risk that previously announced or contemplated property sales, loan repayments, and other capital recycling transactions do not occur as anticipated or at all; (iv) the risk that MPT is Total Assets and Revenues not able to attain its leverage, liquidity and cost of capital objectives within 9 a reasonable time period or at all; (v) MPT's ability to obtain or modify the by Asset Type, Operator, State and Country 10 terms of debt financing on attractive terms or at all, as a result of changes in interest rates and other factors, which may adversely impact our ability Rent Coverage 13 to pay down, refinance, restructure or extend our indebtedness as it becomes due, or pursue acquisition and development opportunities; (vi) the Summary of Active Developments ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us; (vii) the ability of and Capital Addition Projects 15 our tenants and operators to operate profitably and generate positive cash flow, remain solvent, comply with applicable laws, rules and regulations in the operation of our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract patients; (viii) the risk that FINANCIAL STATEMENTS we are unable to monetize our investments in certain tenants at full value within a reasonable time period or at all; (ix) the risk that the operations of our tenants will be negatively impacted by changes to Medicaid funding Consolidated Statements of Income 16 introduced by the OBBBA; and (ix) the risks and uncertainties of litigation Consolidated Balance Sheets 17 or other regulatory proceedings. The risks described above are not exhaustive and additional factors could 16 adversely affect our business and financial performance, including the risk Investments in Unconsolidated Real Estate factors discussed under the section captioned "Risk Factors" in our Annual Joint Ventures 18 Reports on Form 10-K and our Quarterly Reports on Form 10-Q, and as may be updated in our other filings with the SEC. Forward-looking statements are inherently uncertain and actual performance or outcomes may Investments in Unconsolidated Operating Entities 19 vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned to not place undue reliance on forward-looking statements as predictions of future Appendix—Non-GAAP Reconciliations 20 events. We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made. Pictured above: Royal Marsden Cavendish Square—London, England—Operated by NHS. On the cover: Genolier Innovation Hub—Genolier, Switzerland—Operated by Swiss Medical Network. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 2

![LOGO](g67253g12a01.jpg)

------

COMPANY OVERVIEW M edical Properties Trust, Inc. is a self-advised MPT's financing model facilitates acquisitions real estate investment trust formed in 2003 and recapitalizations and allows operators to acquire and develop net-leased hospital facilities. of hospitals to unlock the value of their real From its inception in Birmingham, Alabama, the estate assets to fund facility improvements, Company has grown to become one of the world's technology upgrades and other investments largest owners of hospital real estate. in operations. of June 30, 2025. 392 53 ~39,000 31 9 properties operators beds U.S. states countries MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 3

![LOGO](g67253g00a13.jpg)

------

MPT Officers Edward K. Aldag, Jr. Chairman, President and Chief Executive Officer R. Steven Hamner Executive Vice President and Chief Financial Officer J. Kevin Hanna Senior Vice President, Controller and Chief Accounting Officer Rosa H. Hooper Senior Vice President of Operations and Secretary Larry H. Portal Senior Vice President, Senior Advisor to the CEO Charles R. Lambert Senior Vice President of Finance and Treasurer R. Lucas Savage Vice President, Head of Global Acquisitions Board of Directors Corporate Headquarters Edward K. Aldag, Jr. G. Steven Dawson Medical Properties Trust, Inc. R. Steven Hamner 1000 Urban Center Drive, Suite 501 Caterina A. Mozingo Birmingham, AL 35242 Emily W. Murphy Elizabeth N. Pitman (205) 969-3755 D. Paul Sparks, Jr. (205) 969-3756 (fax) Michael G. Stewart www.medicalpropertiestrust.com C. Reynolds Thompson, III MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 4

![LOGO](g67253g14a01.jpg)

------

INVESTOR RELATIONS Contact Drew Babin, Head of Financial Strategy and Investor Relations (646) 884-9809 or dbabin@medicalpropertiestrust.com Transfer Stock Exchange Agent Listing and Trading Symbol Equniti Trust Company, LLC New York Stock Exchange 28 Liberty Street, Floor 53 (NYSE): MPW New York, NY 10005 https://equiniti.com/us

![LOGO](g67253g00a15.jpg)

------

FINANCIAL INFORMATION RECONCILIATION OF NET LOSS TO FUNDS FROM OPERATIONS (Unaudited) (Amounts in thousands, except per share data) For the Three Months Ended For the Six Months Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 FFO INFORMATION: Net loss attributable to MPT common stockholders $(98,357) $(320,635) $(216,632) $(1,196,260) Participating Net loss, less securities' participating share in securities' earnings share in earnings (224) (654) (341) (654) $(98,581) $(321,289) $(216,973) $(1,196,914) Depreciation and amortization 81,332 117,239 158,223 211,482 Gain Real estate on sale impairment of real estate (recoveries) charges (17,715) (5,212) (384,824) 499,324 (13,271) 47,968 (383,401) 499,324 Funds from operations $(40,176) $(89,550) $(24,053) $(869,509) Other impairment charges, net 19,613 50,073 33,511 744,978 Litigation, bankruptcy and other costs (A) 2,156 11,738 12,203 17,608 Share-based compensation (fair value adjustments) (9,540)—(13) -Non-cash fair value adjustments 108,827 159,247 135,436 380,523 Tax rate changes and other 19 4,895 1,121 4,588 Debt refinancing and unutilized financing costs 463 2,964 4,259 2,964 Normalized funds from operations $81,362 $139,367 $162,464 $281,152 Certain non-cash and related recovery (A) information: Share-based compensation $10,397 $8,521 $18,535 $16,154 Debt costs amortization (B) $6,984 $4,936 $12,990 $9,775 Non-cash rent and interest revenue (C) $—$—$—$-Cash recoveries of non-cash rent and interest revenue $538 $540 $1,064 $6,288 Straight-line rent revenue from operating and finance leases $(42,638) $(40,786) $(85,257) $(88,032) PER DILUTED SHARE DATA: Net loss, less participating securities' share in earnings $(0.16) $(0.54) $(0.36) $(1.99) Depreciation and amortization 0.13 0.20 0.26 0.35 Gain on sale of real estate (0.01) (0.64) (0.02) (0.64) Real estate impairment (recoveries) charges (0.03) 0.83 0.08 0.83 Funds from operations $(0.07) $(0.15) $(0.04) $(1.45) Other impairment charges, net 0.04 0.08 0.05 1.25 Litigation, bankruptcy and other costs—0.02 0.02 0.03 Share-based compensation (fair value adjustments) (A) (0.02) — -Non-cash fair value adjustments 0.19 0.27 0.23 0.63 Tax rate changes and other—0.01—0.01 Debt refinancing and unutilized financing costs — 0.01—Normalized funds from operations $0.14 $0.23 $0.27 $0.47 Certain non-cash and related recovery information: Share-based compensation (A) $0.02 $0.01 $0.03 $0.03 Debt costs amortization $0.01 $0.01 $0.02 $0.02 Non-cash rent and interest revenue (B) $—$—$—$-Cash recoveries of non-cash rent and interest revenue (C) $—$—$—$0.01 Straight-line rent revenue from operating and finance leases $(0.07) $(0.07) $(0.14) $(0.15) Notes: Investors and analysts following the real estate industry utilize funds from operations ("FFO") as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate Investment Trusts, or Nareit, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization, including amortization related to in-place lease intangibles, and after adjustments for unconsolidated partnerships and joint ventures. In addition to presenting FFO in accordance with the Nareit definition, we disclose normalized FFO, which adjusts FFO for items that relate to unanticipated or non-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts. We believe that the use of FFO, combined with the required GAAP presentations, improves the understanding of our operating results among investors and the use of normalized FFO makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs (if any not paid by our tenants) to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our results of operations or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity. Certain line items above (such as depreciation and amortization) include our share of such income/expense from unconsolidated joint ventures. These amounts are included with all activity of our equity interests in the "Earnings (loss) from equity interests" line on the consolidated statements of income. (A) Total share-based compensation expense is $0.9 million and $18.5 million for the three and six months ended June 30, 2025, respectively, (including certain awards that are to be settled in cash). Cash-settled awards are typically recorded in accordance with GAAP at fair value and measured at each balance sheet date until settlement. The resulting fluctuations, which are primarily driven by changes in our stock price rather than operational performance, can introduce significant volatility in our earnings. To enhance comparability and provide a more stable view of performance over time, NFFO reflects a $(9.5) million and less than $(0.1) million adjustment in the three and six months ended June 30, 2025, respectively, to arrive at total share-based compensation expense using grant date fair value for all awards (including cash-settled awards) of $10.4 million and $18.5 million for the three and six months ended June 30, 2025. (B) Includes revenue accrued during the period but not received in cash, such as deferred rent, payment-in-kind ("PIK") interest or other accruals. (C) Includes cash received to satisfy previously accrued non-cash revenue, such as the cash receipt of previously deferred rent or PIK interest. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 6

![LOGO](g67253g16a01.jpg)

------

FINANCIAL INFORMATION (As of June 30, 2025) ($ amounts in thousands) DEBT SUMMARY Debt Instrument Rate Type Rate Balance 2026 Secured Credit Facility Revolver(A)(B) Variable 5.960% $553,437 2027 Secured Term Loan Variable 6.677% 200,000 0.993% Notes Due 2026 (€500M)(B) Fixed 0.993% 589,350 5.000% Notes Due 2027 Fixed 5.000% 1,400,000 3.692% Notes Due 2028 (Ł600M)(B) Fixed 3.692% 823,920 4.625% Notes Due 2029 Fixed 4.625% 900,000 3.375% Notes Due 2030 (Ł350M)(B) Fixed 3.375% 480,620 3.500% Notes Due 2031 Fixed 3.500% 1,300,000 7.000% Secured Notes Due 2032 (€1B)(B) Fixed 7.000% 1,178,700 8.500% Secured Notes Due 2032 Fixed 8.500% 1,500,000 2034 Secured GBP Term Loan (Ł631M)(B) Fixed 6.877% 867,010 $9,793,037 Debt issuance costs and discount (144,002) Weighted average rate 5.411% $9,649,035 Variable 8% Fixed 92% (A) As part of our Credit Facility amendment on February 13, 2025, we provided notice to extend the maturity to June 30, 2027, subject to the satisfaction of certain other conditions. (B) Non-USD denominated debt converted to U.S. dollars at June 30, 2025. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 7

![LOGO](g67253g00a17.jpg)

------

FINANCIAL INFORMATION (As of June 30, 2025) ($ amounts in thousands) DEBT MATURITIES Year Senior Notes Term Loans/Revolver Total Debt % of Total 2025 $—$—$—0.0% 2026 589,350 553,437 (A) 1,142,787 11.7% 2027 1,400,000 200,000 1,600,000 16.3% 2028 823,920—823,920 8.4% 2029 900,000—900,000 9.2% 2030 480,620—480,620 4.9% 2031 1,300,000—1,300,000 13.3% 2032 2,678,700—2,678,700 27.3% 2033 ——0.0% 2034—867,010 867,010 8.9% Totals $8,172,590 $1,620,447 $9,793,037 100.0% DEBT BY LOCAL CURRENCY Senior Notes Term Loans/Revolver Total Debt % of Total United States dollars $5,100,000 $570,000 $5,670,000 57.9% British pound sterling 1,304,540 867,010 2,171,550 22.2% Euros 1,768,050 117,870 1,885,920 19.2% Swiss francs—65,567 65,567 0.7% Totals $8,172,590 $1,620,447 $9,793,037 100.0% DEBT METRICS (B) For the Three Months Ended June 30, 2025 Adjusted Net Debt to Annualized EBITDAre Ratios: Adjusted Net Debt $8,632,770 Adjusted Annualized EBITDAre $902,448 Adjusted Net Debt to Adjusted Annualized EBITDAre Ratio 9.6x Adjusted Net Debt $8,632,770 Transaction Adjusted Annualized EBITDAre $899,964 Adjusted Net Debt to Transaction Adjusted Annualized EBITDAre Ratio 9.6x Leverage Ratio: Unsecured Debt $5,493,890 Secured Debt 4,299,147 Total Debt $9,793,037 Total Gross Assets(C) $16,750,015 Financial Leverage 58.5% Interest Coverage Ratio: Interest Expense $129,709 Capitalized Interest 3,239 Debt Costs Amortization (6,705) Total Interest $126,243 Adjusted EBITDAre $225,612 Adjusted Interest Coverage Ratio 1.8x (A) As part of our Credit Facility amendment on February 13, 2025, we provided notice to extend the maturity to June 30, 2027, subject to the satisfaction of certain other conditions. (B) Not intended to reflect covenants per debt agreements. (C) Total Gross Assets equals total assets plus real estate accumulated depreciation and amortization. See appendix for reconciliation of Non-GAAP financial measures. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 8

![LOGO](g67253g00a18.jpg)

------

PORTFOLIO INFORMATION LEASE AND LOAN MATURITY SCHEDULE (A) ($ amounts in thousands) (B) (C) (D) Percentage of Total Years of Maturities Total Properties Base Rent/Interest Base Rent/Interest 2025 1 $—0.0% 2026 1 228 0.0% 2027 3 4,881 0.4% 2028 9 23,169 2.0% 2029 6 16,685 1.5% 2030 9 6,369 0.6% 2031 5 6,437 0.6% 2032 21 59,047 5.2% 2033 5 6,201 0.5% 2034 14 107,883 9.5% Thereafter 297 907,504 79.7% 371 # $1,138,404 100.0% Percentage of total base rent/interest 100% 90% 80% 79.7% 70% 60% 50% 40% 30% 20% 9.5% 10% 5.2% 0.0% 0.0% 0.4% 2.0% 1.5% 0.6% 0.6% 0.5% 0% (A) Schedule includes leases and mortgage loans and related terms as of June 30, 2025. (B) Lease/Loan expiration is based on the fixed term of the lease/loan and does not factor in potential renewal or other options provided for in our agreements. (C) Reflects all properties, including those that are part of joint ventures, except vacant properties (less than 1% of total assets), facilities that are under development, and transitioning properties. (D) Represents base rent/interest income contractually owed per the lease/loan agreements on an annualized basis as of period end (including foreign currency exchange rates) but does not include tenant recoveries, additional rents and other lease-related adjustments to revenue (i.e., straight-line rents and deferred revenues), or any reserves or write-offs.

![LOGO](g67253g19a01.jpg)

------

PORTFOLIO INFORMATION TOTAL ASSETS AND REVENUES BY ASSET TYPE (June 30, 2025) ($ amounts in thousands) Total Percentage of Q2 2025 Percentage of Asset Types Properties (A) Assets Total Assets Revenues Q2 2025 Revenues General Acute Care Hospitals 174 $8,992,213 59.4% $147,648 61.4% Behavioral Health Facilities 69 2,506,704 16.5% 53,545 22.3% Post Acute Care Facilities 128 1,655,572 10.9% 37,176 15.5% Freestanding ER/Urgent Care Facilities 21 115,667 0.8% 1,990 0.8% Other—1,880,272 12.4% — Total 392 $15,150,428 100.0% $240,359 100.0% Note: Investments in operating entities are allocated pro rata based on the gross book value of the real estate. Such pro rata allocations are subject to change from period to period. (A) Reflects total assets on our consolidated balance sheets. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 10

![LOGO](g67253g00a20.jpg)

------

PORTFOLIO INFORMATION TOTAL ASSETS—LARGEST INDIVIDUAL FACILITY (June 30, 2025) COMPREHENSIVE PROPERTY-LEVEL UNDERWRITING FRAMEWORK Largest Individual MPT invests in real estate, not the consolidated financial performance of its Operators Facility as a Percentage tenants. Each facility is underwritten for characteristics that make the of Total Assets(A) infrastructure attractive to any experienced, competent operator—not just the current tenant. If we have underwritten these correctly, then coupled 1.4% with our absolute net master lease structure, our real estate will be Circle Health attractive to a replacement operator, should we find it necesssary to Priory Group 0.9% 1.8% transition. Such underwriting characteristics include: Healthcare Systems of America Swiss Medical Network 1.7% Lifepoint Behavioral Health 0.5% Physical Quality Competition 48 operators 1.6% Largest Individual Facility Investment is Less Than 2% of MPT Investment Portfolio Demographics Financial and Market TOTAL ASSETS AND REVENUES BY OPERATOR (June 30, 2025) ($ amounts in thousands) Total Percentage of Q2 2025 Percentage of Operators Properties (A) Assets Total Assets Revenues Q2 2025 Revenues Circle Health 36 $2,195,038 14.5% $53,725 22.4% Priory Group 37 1,340,466 8.8% 26,456 11.0% Healthcare Systems of America 8 1,204,109 7.9% 7,769 3.2% Swiss Medical Network 20 863,343 5.7% 939 0.4% Lifepoint Behavioral Health 19 816,943 5.4% 20,436 8.5% MEDIAN 81 679,841 4.5% 8,532 3.5% Prospect Medical Holdings 13 662,021 4.4%—0.0% Ernest Health 28 616,810 4.1% 19,669 8.2% Lifepoint Health 8 467,900 3.1% 15,314 6.4% Ramsay Health Care 8 418,970 2.8% 6,771 2.8% 43 operators 134 4,004,715 26.4% 80,748 33.6% Other—1,880,272 (B) 12.4% — Total 392 $15,150,428 100.0% $240,359 100.0% Note: Investments in operating entities are allocated pro rata based on the gross book value of the real estate. Such pro rata allocations are subject to change from period to period. (A) Reflects total assets on our consolidated balance sheets. (B) Includes our PHP Holdings investment of approximately $2.3 million. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 11

![LOGO](g67253g21a01.jpg)

------

PORTFOLIO INFORMATION TOTAL ASSETS AND REVENUES BY U.S. STATE AND COUNTRY (June 30, 2025) ($ amounts in thousands) Total Percentage of Q2 2025 Percentage of U.S. States and Other Countries Properties (A) Assets Total Assets Revenues Q2 2025 Revenues Texas 45 $1,415,603 9.3% $25,630 10.7% California 17 943,646 6.3% 15,464 6.4% Florida 6 845,268 5.6% 4,876 2.0% Arizona 10 384,310 2.5% 9,634 4.0% Ohio 9 332,337 2.2% 6,459 2.7% 26 Other States 81 2,621,863 17.3% 64,004 26.6% Other—1,031,221 6.8% — United States 168 $7,574,248 50.0% $126,067 52.4% United Kingdom 92 $4,319,502 28.5% $93,924 39.1% Switzerland 20 863,343 5.7% 939 0.4% Germany 85 756,490 5.0% 10,699 4.5% Spain 9 285,895 1.9% 3,213 1.3% Other Countries 18 501,899 3.3% 5,517 2.3% Other—849,051 5.6% — International 224 $7,576,180 50.0% $114,292 47.6% Total 392 $15,150,428 100.0% $240,359 100.0% Note: Investments in operating entities are allocated pro rata based on the gross book value of the real estate. Such pro rata allocations are subject to change from period to period. (A) Reflects total assets on our consolidated balance sheets. [Graphic Appears Here]

![LOGO](g67253g00a22.jpg)

------

PORTFOLIO INFORMATION TOTAL PORTFOLIO TTM EBITDARM(A)(B) RENT COVERAGE YoY and SEQUENTIAL QUARTER COMPARISONS BY PROPERTY TYPE Notes: All data presented is on a trailing twelve month ("TTM") basis. For properties acquired in the preceding twelve months, data is for the period between MPT acquisition and March 31, 2025. (A) EBITDARM is facility-level earnings before interest, taxes, depreciation, amortization, rent and management fees. EBITDARM includes normal GAAP expensed maintenance and repair costs. EBITDARM does not give effect for capitalized expenditures that extend the life or improve the facility and equipment to increase revenues at the facility. The majority of these types of capital expenditures are financed and do not have an immediate cash impact. MPT's rent has priority and is not subordinate to capitalized expenses. In addition, EBITDARM does not represent property net income or cash flows from operations and should not be considered an alternative to those indicators. EBITDARM figures utilized in calculating coverages presented are based on financial information provided by MPT's tenants. MPT has not independently verified this information, but has no reason to believe this information is inaccurate in any material respect. TTM Coverages are calculated based on actual, unadjusted EBITDARM results as presented in tenant financial reporting and cash rent paid to MPT, except as noted below.—EBITDARM figures for California hospitals include amounts expected to be received under the Hospital Quality Assurance Fee ("HQAF") Program 8. The HQAF amounts are based on the current payment model from the California Hospital Association which was approved by CMS on December 19, 2023. (B) General Acute Care coverages, Behavioral Health coverages and Total Portfolio coverages do not include Prospect Medical Holdings (PMH) facilities due to restructuring, and former Steward Health Care facilities due to re-tenanting. (C) Post Acute Care Facilities property type includes both Inpatient Rehabilitation Hospitals and Long Term Acute Care Hospitals. (D) Reflects percentage of total assets on June 30, 2025 balance sheet. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 13

![LOGO](g67253g23a01.jpg)

------

PORTFOLIO INFORMATION TOTAL PORTFOLIO TTM EBITDARM RENT COVERAGE EBITDARM RENT COVERAGE: OPERATORS WITH PROPERTY-LEVEL REPORTING Net Investment (B) Tenant (A) Primary Property Type TTM EBITDARM Rent Coverage (in thousands) Priory Group $1,296,382 Behavioral 2.3x MEDIAN 679,841 Post Acute 1.8x Ernest Health 616,810 Post Acute 2.3x Aspris Children's Services 255,546 Behavioral 2.1x Surgery Partners 219,600 General Acute 6.8x Pipeline Health System 206,666 General Acute 2.2x Vibra Healthcare 188,159 Post Acute 1.8x Prime Healthcare 158,957 General Acute 1.8x IMED Hospitales 136,203 General Acute 1.8x Cordiant Healthcare Services 88,663 General Acute 0.5x Other Reporting Tenants 454,707 Various 2.9x Total $4,301,534 2.4x Net Investment Tenant (A) Primary Property Type TTM EBITDARM Rent Coverage (in thousands) International Operator 1 $2,146,660 General Acute 2.7x Domestic Operator 1 467,900 General Acute 2.9x Domestic Operator 2 329,112 General Acute 2.3x Domestic Operator 3 816,943 Behavioral 1.8x Domestic Operator 4 81,185 General Acute 8.0x Total $3,841,800 2.7x PROPERTY-LEVEL REPORTING NOT REQUIRED AND/OR NOT AVAILABLE Net Investment Tenant (A) Primary Property Type Comments (in thousands) U.S. hospital operator with eight community hospitals across Healthcare Systems of America $1,126,666 General Acute three states Prospect Medical Holdings 648,521 General Acute In court restructuring ongoing Swiss Medical Network 602,321 General Acute Second largest group of private hospitals in Switzerland One of the largest healthcare operators in the world; Parent Ramsay Health Care UK 418,970 General Acute guaranty; Investment grade-rated Pihlajalinna 224,636 General Acute One of Finland's leading providers of social and health services U.S. hospital operator with twelve community hospitals across Quorum Health 140,338 General Acute nine states One of the largest nonprofit healthcare operators in the U.S.; CommonSpirit Health 134,439 General Acute Investment grade-rated One of Arizona's largest nonprofit healthcare systems; HonorHealth 134,438 General Acute Investment grade-rated Saint Luke's—Kansas City 121,010 General Acute Investment grade-rated NHS 90,903 General Acute Single-payor government entity in UK U.S. hospital operator with nine medical centers across four Insight Health 65,834 General Acute states U.S. hospital operator with four hospitals in Southern College Health 60,251 Behavioral California and one in Arizona U.S. hospital operator with nine behavioral health hospitals; NeuroPsychiatric Hospitals 25,983 Behavioral Parent guaranty Publicly-traded U.S. hospital operator with substantial Community Health Systems 24,714 General Acute operating history Total $3,819,024 Above data represents approximately 92% of MPT Total Real Estate Investment Notes: All data presented is on a trailing twelve month ("TTM") basis. For properties acquired in the preceding twelve months, data is for the period between MPT acquisition and March 31, 2025. (A) Investment figures exclude equity investments, non-real estate loans, freestanding ER/urgent care facilities, and facilities under development. (B) General Acute Care coverages, Behavioral Health coverages and Total Portfolio coverages do not include Prospect Medical Holdings (PMH) facilities due to restructuring, and former Steward Health Care facilities due to re-tenanting. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 14

![LOGO](g67253g00a24.jpg)

------

PORTFOLIO INFORMATION SUMMARY OF ACTIVE DEVELOPMENT AND CAPITAL ADDITION PROJECTS AS OF JUNE 30, 2025(A) (Amounts in thousands) Costs Incurred as of Estimated Construction Operator Location Commitment Cost Remaining June 30, 2025 Completion Date Lifepoint Behavioral Kansas $20,183 $16,761 $3,422 3Q25 Surgery Partners Idaho 15,993 13,345 2,648 3Q25 Lifepoint Behavioral Arizona 10,659 5,320 5,339 1Q26 IMED Spain 41,211 35,654 5,557 1Q26 IMED Spain 56,498 29,877 26,621 2Q26 Other Various 554 210 344 2Q26 $145,098 $101,167 $43,931 (A) In addition to the above projects, the costs of which will be included in lease bases upon which the lessees will pay rent, we are constructing two hospitals for which there is no presently-identified lessee; these projects were both originally planned to be operated by a former tenant. We are presently completing construction to the stage where the building is "weathered in" and environmentally secure so as to physically protect our investment while we actively market the hospitals for sale or lease. As of June 30, 2025, we estimate that the cost to complete construction to this stage, plus costs of additional construction that we believe will be more efficient if completed in the near term (such as now electing to accelerate completion of a parking structure at one hospital), approximates between $50 million and $55 million. If we agree to lease terms for any prospective tenant, we expect such terms will include construction specifications of such prospective lessee, and we may elect to fund such completion for addition to the final lease base upon which we would be paid rent. Alternatively, we may elect to sell one or both of the facilities, in which case we would not expect to incur material additional costs. Since approximately 2022, we have planned and commenced construction of a built-to-suit headquarters facility and estimate its completion and occupancy by 2025's fourth quarter. Total costs to complete, including furnishings, interior buildout, relocation and other costs are estimated to be between $45 million and $55 million. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 15

![LOGO](g67253g25a01.jpg)

------

FINANCIAL STATEMENTS CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (Amounts in thousands, except per share data) For the Three Months Ended For the Six Months Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 REVENUES Rent billed $177,860 $183,764 $343,050 $383,063 Straight-line rent 39,665 38,381 79,792 83,117 Income from financing leases 9,923 27,641 19,828 44,034 Interest and other income 12,911 16,774 21,488 27,662 Total revenues 240,359 266,560 464,158 537,876 EXPENSES Interest 129,709 101,430 245,510 210,115 Real estate depreciation and amortization 66,717 102,240 131,289 177,826 Property-related(A) 10,863 7,663 17,898 12,481 General and administrative 26,197 35,327 68,108 68,675 Total expenses 233,486 246,660 462,805 469,097 OTHER (EXPENSE) INCOME Gain on sale of real estate 5,212 384,824 13,271 383,401 Real estate and other impairment charges, net (1,421) (137,419) (77,523) (830,507) Earnings (loss) from equity interests 25,324 (401,757) 39,310 (391,208) Debt refinancing and unutilized financing benefit (costs) 181 (2,964) (3,615) (2,964) Other (including fair value adjustments on securities) (124,434) (167,686) (169,640) (397,031) Total other expense (95,138) (325,002) (198,197) (1,238,309) Loss before income tax (88,265) (305,102) (196,844) (1,169,530) Income tax expense (9,803) (14,557) (19,240) (25,506) Net loss (98,068) (319,659) (216,084) (1,195,036) Net income attributable to non-controlling interests (289) (976) (548) (1,224) Net loss attributable to MPT common stockholders $(98,357) $(320,635) $(216,632) $(1,196,260) EARNINGS PER COMMON SHARE—BASIC AND DILUTED Net loss attributable to MPT common stockholders $(0.16) $(0.54) $(0.36) $(1.99) WEIGHTED AVERAGE SHARES OUTSTANDING—BASIC 600,814 600,057 600,733 600,181 WEIGHTED AVERAGE SHARES OUTSTANDING—DILUTED 600,814 600,057 600,733 600,181 $—$—DIVIDENDS DECLARED PER COMMON SHARE $0.08 $0.30 $0.16 $0.30 (A) Includes $5.1 million and $4.9 million of ground lease and other expenses (such as property taxes and insurance) paid directly by us and reimbursed by our tenants for the three months ended June 30, 2025 and 2024, respectively, and $7.1 and $7.2 million for the six months ended June 30, 2025 and 2024, respectively. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 16

![LOGO](g67253g26a01.jpg)

------

FINANCIAL STATEMENTS CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except per share data) June 30, 2025 December 31, 2024 (Unaudited) (A) ASSETS Real estate assets Land, buildings and improvements, intangible lease assets, and other $11,892,237 $11,259,842 Investment in financing leases 1,023,415 1,057,770 Real estate held for sale—34,019 Mortgage loans 123,887 119,912 Gross investment in real estate assets 13,039,539 12,471,543 Accumulated depreciation and amortization (1,599,587) (1,422,948) Net investment in real estate assets 11,439,952 11,048,595 Cash and cash equivalents 509,828 332,335 Interest and rent receivables 28,644 36,327 Straight-line rent receivables 825,845 700,783 Investments in unconsolidated real estate joint ventures 1,360,151 1,156,397 Investments in unconsolidated operating entities 323,383 439,578 Other loans 149,018 109,175 Other assets 513,607 471,404 Total Assets $15,150,428 $14,294,594 LIABILITIES AND EQUITY Liabilities Debt, net $9,649,035 $8,848,112 Accounts payable and accrued expenses 494,783 454,209 Deferred revenue 23,513 29,445 Obligations to tenants and other lease liabilities 149,287 129,045 Total Liabilities 10,316,618 9,460,811 Equity Preferred stock, $0.001 par value. Authorized 10,000 shares; no shares outstanding —Common stock, $0.001 par value. Authorized 750,000 shares; issued and outstanding—600,814 shares at June 30, 2025 and 600,403 shares at December 31, 2024 601 600 Additional paid-in capital 8,598,211 8,584,917 Retained deficit (3,971,824) (3,658,516) Accumulated other comprehensive income (loss) 205,768 (94,272) Total Medical Properties Trust, Inc. stockholders' equity 4,832,756 4,832,729 Non-controlling interests 1,054 1,054 Total Equity 4,833,810 4,833,783 Total Liabilities and Equity $15,150,428 $14,294,594 (A) Financials have been derived from the prior year audited financial statements. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 17

![LOGO](g67253g00a27.jpg)

------

FINANCIAL STATEMENTS INVESTMENTS IN UNCONSOLIDATED REAL ESTATE JOINT VENTURES (As of and for the three months ended June 30, 2025) (Unaudited) ($ amounts in thousands) Swiss Medical HM MEDIAN(B) (C) CommonSpirit(D) Policlinico di Monza(E) (F) Total MPT Pro Rata Share Network Hospitales Gross real estate $2,099,036 $1,903,718 $1,336,071 $197,571 $399,071 $5,935,467 $2,995,173 Cash 31,054 2,459 3,928 18,164 2,458 58,063 28,420 Accumulated depreciation and amortization (333,950) (225,187)—(42,356) (47,703) (649,196) (367,250) Other assets 119,655 84,521 8,288 4,088 10,694 227,246 127,925 Total Assets $1,915,795 $1,765,511 $1,348,287 $177,467 $364,520 $5,571,580 $2,784,268 Debt (third party) $791,411 $734,874 $770,000 $—$152,797 $2,449,082 $1,171,760 Other liabilities 151,079 170,178 41,606 9,306 94,706 466,875 252,357 (A) Equity and shareholder loans 973,305 860,459 536,681 168,161 117,017 2,655,623 1,360,151 Total Liabilities and Equity $1,915,795 $1,765,511 $1,348,287 $177,467 $364,520 $5,571,580 $2,784,268 MPT share of real estate joint venture 50% 70% 25% 50% 45% Total $486,653 $602,321 $134,439 $84,080 $52,658 $1,360,151 Swiss Medical HM MEDIAN(B) (C) CommonSpirit(D) Policlinico di Monza(E) (F) Total MPT Pro Rata Share Network Hospitales Total revenues $35,451 $21,803 $24,865 $3,345 $4,034 $89,498 $42,704 Other expenses (income): Property-related $2,173 $1,173 $(14) $917 $7 $4,256 $2,366 Interest 14,485 3,630 12,603—575 31,293 13,200 Real estate depreciation and amortization 11,909 10,039—1,085 2,139 25,172 14,487 General and administrative 1,192 339—(65) 14 1,480 807 Fair value adjustments — (60,517) — (60,517) (15,159) Non-controlling interest expense — 124 — 124 31 Income taxes 1,558 996 — 331 2,885 1,625 Total other expenses (income) $31,317 $16,177 $(47,804) $1,937 $3,066 $4,693 $17,357 Net income $4,134 $5,626 $72,669 $1,408 $968 $84,805 $25,347 MPT share of real estate joint venture 50% 70% 25% 50% 45% Earnings from equity interests $2,067 $3,937 $18,203 $704 $436 $25,347 (G) (A) Includes a €309 million loan from both shareholders. (B) MPT managed joint venture of 71-owned German facilities that are fully leased. (C) Represents ownership in Infracore, which owns and leases 18 Switzerland facilities. We also have two Infracore facilities currently under development. (D) Represents ownership in five Utah facilities that are fully leased. The joint venture elected to apply specialized accounting and reporting for investment companies under Topic 946, which measures the underlying investments at fair value. For this quarter, our share of the joint venture's favorable fair value adjustment was $15.2 million, primarily related to real estate. (E) Represents ownership in eight Italian facilities that are fully leased. (F) Represents ownership in two Spanish facilities that are fully leased. (G) Excludes $23,000 of amortization of equity investment costs. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 18

![LOGO](g67253g28a01.jpg)

------

FINANCIAL STATEMENTS INVESTMENTS IN UNCONSOLIDATED OPERATING ENTITIES (Amounts in thousands) OPERATING ENTITY INVESTMENT FRAMEWORK MPT's hospital expertise and comprehensive underwriting process allows for opportunistic investments in hospital operations. • Passive investments typically needed in order to acquire the larger real estate • Certain of these investments entitle us to customary minority rights and transactions. protections. • Cash payments go to previous owner and not to the tenant, with limited • Typically, no additional operating loss exposure beyond our investment. exceptions. • Proven track record of successful investments, including Ernest Health, Capella • Operators are vetted as part of our overall underwriting process. Healthcare and Springstone. • Potential for outsized returns and organic growth. Investment Ownership Operator as of Structure Interest June 30, 2025 Includes our passive equity ownership interest, along with a CHF 37 million loan as part of a syndicated Swiss Medical Network $197,413 8.9% loan facility. Includes our passive equity ownership interest in Aevis, a public healthcare investment company. Our Aevis 63,609 4.6% original investment of CHF 47 million is marked-to-market quarterly. In order to close the 2021 acquisition of 35 facilities, we made an investment in Priory, proceeds of which Priory Group 44,084 9.2% were paid to the former owner. Includes our passive equity ownership interest in Aspris, a spin-off of Priory's education and children's Aspris 15,929 9.2% services line of business. PHP Holdings 2,348 This investment was liquidated on July 1, 2025, resulting in proceeds of $2.3 million. Total $323,383 INVESTMENTS IN UNCONSOLIDATED OPERATING ENTITIES AS A PERCENTAGE OF TOTAL ASSETS 7% MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 19

![LOGO](g67253g00a29.jpg)

------

APPENDIX—NON-GAAP RECONCILIATIONS ADJUSTED NET DEBT/ANNUALIZED EBITDAre (Unaudited) (Amounts in thousands) For the Three Months Ended June 30, 2025 ADJUSTED EBITDAre RECONCILIATION Net loss $(98,068) Add back: Interest 129,709 Income tax 9,803 Depreciation and amortization 68,238 Gain on sale of real estate (5,212) Real estate impairment recoveries (13,315) Adjustment to reflect MPT's share of unlevered EBITDAre from unconsolidated real estate joint ventures(A) 6,941 2Q 2025 EBITDAre $98,096 Share-based compensation 857 Other impairment charges, net 15,213 Litigation, bankruptcy and other costs 2,156 Debt refinancing and unutilized financing costs 463 Non-cash fair value adjustments 108,827 Annualized 2Q 2025 Adjusted EBITDAre $225,612 $902,448 Adjustments for mid-quarter investment activity(B) (621) 2Q 2025 Transaction Adjusted EBITDAre $224,991 $899,964 ADJUSTED NET DEBT RECONCILIATION Total debt at June 30, 2025 $9,649,035 Less: Cash at June 30, 2025 (509,828) Less: Cash funded for development and capital addition projects at June 30, 2025(C) (506,437) Adjusted Net Debt $8,632,770 Investors and analysts following the real estate industry utilize net debt (debt less cash) to EBITDAre as a measurement of leverage that shows how many years it would take for us to pay back our debt, assuming net debt and EBITDAre are held constant. In our calculation, we start with EBITDAre , as defined by Nareit, which is net income before interest expense, income tax expense, depreciation and amortization, losses/gains on disposition of depreciated property, impairment losses, and adjustments to reflect our share of EBITDAre from unconsolidated real estate joint ventures. We then adjust EBITDAre for non-cash share-based compensation, non-cash fair value adjustments and other items that would make comparison of our operating results with prior periods and other companies more meaningful, to derive Adjusted EBITDAre . We adjust net debt for cash funded for building improvements in progress and construction in progress for which we are not yet receiving rent to derive Adjusted Net Debt. We adjust Adjusted EBITDAre for the effects from investments and capital transactions that were completed during the period, assuming such transactions were consummated/fully funded as of the beginning of the period to derive Transaction Adjusted EBITDAre . Although non-GAAP measures, we believe Adjusted Net Debt, Adjusted EBITDAre , and Transaction Adjusted EBITDAre are useful to investors and analysts as they allow for a more current view of our credit quality and allow for the comparison of our credit strength between periods and to other real estate companies without the effect of items that by their nature are not comparable from period to period. (A) Includes only the unlevered portion of our share of EBITDAre from unconsolidated real estate joint ventures, as we have excluded any net debt from our unconsolidated real estate joint ventures in the Adjusted Net Debt line. We believe this adjustment is needed to appropriately reflect the relationship between EBITDAre and net debt. (B) Reflects a full quarter impact from our mid-quarter investments, disposals, and loan payoffs. (C) Reflects development and capital improvement projects that are in process and not yet generating a cash return. MEDICAL PROPERTIES TRUST \| SUPPLEMENTAL INFORMATION \| Q2 2025 20

![LOGO](g67253g30a01.jpg)

------

1000 Urban Center Drive, Suite 501 Birmingham, AL 35242 (205) 969-3755 NYSE: MPW www.medicalpropertiestrust.com Contact: Drew Babin, Head of Financial Strategy and Investor Relations (646) 884-9809 or dbabin@medicalpropertiestrust.com

![LOGO](g67253g00a31.jpg)